ENTBF - Entheon Biomedical to acquire Lobo Genetics

Entheon Biomedical ([[ENTBF]] +2.8%) has entered into a definitive agreement to acquire personalized genetics company Lobo Genetics.Pursuant to the agreement, the company will issue an aggregate of 5M shares to the shareholders of Lobo.Under the deal, which is structured as a three-cornered amalgamation, Lobo will merge with Subco, a newly incorporated and wholly-owned subsidiary of the company.Following the transaction, the amalgamated company will be a wholly-owned subsidiary functioning under the name "Lobo Genetics" and carry on the business of Lobo."This acquisition supports Entheon's genetic-driven approach to developing personalized psychedelic-assisted psychotherapeutic ((PAP)) protocols to treat substance use disorders while providing in-house DNA data analytics, expanded assay development and genetic research capacities," Chief Executive Officer of Entheon, Timothy Ko said.

For further details see:

Entheon Biomedical to acquire Lobo Genetics